Guggenheim Initiates Coverage On Rapport Therapeutics with Buy Rating, Announces Price Target of $65

Benzinga Newsdesk www.benzinga.com Neutral 50.6%

Neg 0% Neu 50.6% Pos 0%

Guggenheim analyst Delma Caiati initiates coverage on Rapport Therapeutics (NASDAQ:RAPP) with a Buy rating and announces Price Target of $65.